サンプル依頼リスト カート
  • English
  • Korean
表紙：日本の塞栓粒子処置の件数：セグメント別、予測（～2030年）
市場調査レポート
商品コード
1267577

日本の塞栓粒子処置の件数：セグメント別、予測（～2030年）

Japan Embolization Particle Procedures Count by Segments and Forecast to 2030
出版日: | 発行: GlobalData | ページ情報: 英文 54 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
日本の塞栓粒子処置の件数：セグメント別、予測（～2030年）
出版日: 2023年04月28日
発行: GlobalData
ページ情報: 英文 54 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、日本における塞栓粒子処置について調査分析し、主な情報とセグメントごとの処置件数のデータを提供しています。

目次

第1章 目次

第2章 イントロダクション

  • このレポートの内容
  • 塞栓粒子処置、セグメンテーション
  • レポートで取り上げる処置の定義

第3章 塞栓粒子処置、日本

  • 塞栓粒子処置、日本（2015年～2030年）
    • 動静脈奇形の治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 良性前立腺肥大症の治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 転移性肝疾患を伴う大腸がんの治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 肝細胞がんの治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 肝内胆管がんの治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 転移性肝疾患を伴う神経内分泌腫瘍の治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 転移性肝疾患を伴うその他の腫瘍の治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 腎細胞がんの治療に向けた塞栓粒子処置、日本（2015年～2030年）
    • 子宮筋腫の治療に向けた塞栓粒子処置、日本（2015年～2030年）

第4章 付録

図表

List of Tables

List of Tables

  • Table 1: Embolization Particle Procedures, Japan, 2015-2022
  • Table 2: Embolization Particle Procedures, Japan, 2023-2030
  • Table 3: Embolization Particle Procedures to treat Arteriovenous Malformations, Japan, 2015-2022
  • Table 4: Embolization Particle Procedures to treat Arteriovenous Malformations, Japan, 2023-2030
  • Table 5: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Japan, 2015-2022
  • Table 6: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Japan, 2023-2030
  • Table 7: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Japan, 2015-2022
  • Table 8: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Japan, 2023-2030
  • Table 9: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Japan, 2015-2022
  • Table 10: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Japan, 2023-2030
  • Table 11: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Japan, 2015-2022
  • Table 12: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Japan, 2023-2030
  • Table 13: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Japan, 2015-2022
  • Table 14: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Japan, 2023-2030
  • Table 15: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Japan, 2015-2022
  • Table 16: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Japan, 2023-2030
  • Table 17: Embolization Particle Procedures to treat Renal Cell Carcinoma, Japan, 2015-2022
  • Table 18: Embolization Particle Procedures to treat Renal Cell Carcinoma, Japan, 2023-2030
  • Table 19: Embolization Particle Procedures to treat Uterine Fibroids, Japan, 2015-2022
  • Table 20: Embolization Particle Procedures to treat Uterine Fibroids, Japan, 2023-2030
  • Table 21: Total Number of Primary Research Participants, General Surgery Market, by Country

List of Figures

List of Figures

  • Figure 1: Embolization Particle Procedures, Japan, 2015-2022
  • Figure 2: Embolization Particle Procedures, Japan, 2023-2030
  • Figure 3: Embolization Particle Procedures to treat Arteriovenous Malformations, Japan, 2015-2022
  • Figure 4: Embolization Particle Procedures to treat Arteriovenous Malformations, Japan, 2023-2030
  • Figure 5: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Japan, 2015-2022
  • Figure 6: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Japan, 2023-2030
  • Figure 7: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Japan, 2015-2022
  • Figure 8: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Japan, 2023-2030
  • Figure 9: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Japan, 2015-2022
  • Figure 10: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Japan, 2023-2030
  • Figure 11: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Japan, 2015-2022
  • Figure 12: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Japan, 2023-2030
  • Figure 13: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Japan, 2015-2022
  • Figure 14: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Japan, 2023-2030
  • Figure 15: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Japan, 2015-2022
  • Figure 16: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Japan, 2023-2030
  • Figure 17: Embolization Particle Procedures to treat Renal Cell Carcinoma, Japan, 2015-2022
  • Figure 18: Embolization Particle Procedures to treat Renal Cell Carcinoma, Japan, 2023-2030
  • Figure 19: Embolization Particle Procedures to treat Uterine Fibroids, Japan, 2015-2022
  • Figure 20: Embolization Particle Procedures to treat Uterine Fibroids, Japan, 2023-2030
目次
Product Code: GDMEPD0811C116

Abstract

Japan Embolization Particle Procedures Count by Segments (Embolization Particle Procedures to treat Hepatocellular Carcinoma, Embolization Particle Procedures to treat Intrahepatic Cholangiocarcinoma, Embolization Particle Procedures to treat Uterine Fibroids and Others) and Forecast to 2030

GlobalData's "Japan Embolization Particle Procedures Outlook to 2030" is a comprehensive databook report, covering key procedures data on the Japan Embolization Particle Procedures. The databook report provides procedure volumes within segments - Embolization Particle Procedures to treat Arteriovenous Malformations, Benign prostatic hyperplasia, Colorectal Cancer with Metastatic Liver Disease, Hepatocellular Carcinoma, Intrahepatic cholangiocarcinoma, Neuroendocrine tumors with Metastatic Liver Disease, Other tumors with Metastatic Liver Disease, Renal Cell Carcinoma, Uterine Fibroids

The Japan Embolization Particle Procedures report provides key information and data on -

  • Procedure volume data for Embolization Particle Procedures related to the country. Data is provided from 2015 to 2030.

Scope

Japan Embolization Particle Procedures is segmented as follows -

  • Embolization Particle Procedures to treat Arteriovenous Malformations
  • Embolization Particle Procedures to treat Benign prostatic hyperplasia
  • Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease
  • Embolization Particle Procedures to treat Hepatocellular Carcinoma
  • Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma
  • Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease
  • Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease
  • Embolization Particle Procedures to treat Renal Cell Carcinoma
  • Embolization Particle Procedures to treat Uterine Fibroids

Reasons to Buy

Japan Embolization Particle Procedures report helps you to develop -

  • Business strategies by identifying the key segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Develop investment strategies by identifying the key segments expected to register strong growth in the near future.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 What Is This Report About?
  • 2.2 Embolization Particle Procedures, Segmentation
  • 2.3 Definitions of Procedures Covered in the Report

3 Embolization Particle Procedures, Japan

  • 3.1 Embolization Particle Procedures, Japan, 2015-2030
    • 3.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, Japan, 2015-2030
    • 3.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, Japan, 2015-2030
    • 3.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Japan, 2015-2030
    • 3.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, Japan, 2015-2030
    • 3.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Japan, 2015-2030
    • 3.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Japan, 2015-2030
    • 3.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Japan, 2015-2030
    • 3.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, Japan, 2015-2030
    • 3.1.9 Embolization Particle Procedures to treat Uterine Fibroids, Japan, 2015-2030

4 Appendix

  • 4.1 Research Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Market Modeling and Forecasting
    • 4.1.5 Company Share Analysis
    • 4.1.6 Distribution Share Analysis
    • 4.1.7 Benchmarking
  • 4.2 GlobalData Consulting
  • 4.3 Contact Us
  • 4.4 Disclaimer